DRUGphase3
Vorasidenib
Mechanism
Dual IDH1/2 inhibitor. Approved for glioma, investigating in CCA.
Related claims (50)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug target | Vorasidenib is an inhibitor of mutant IDH1/2 enzymes. | 100% | 41201564 |
| drug efficacy | Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML (clinical trial result). | 100% | 41662580 |
| drug efficacy | Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML (clinical trial result). | 100% | 41662580 |
| drug target | Inhibitors of mutated IDH1 and IDH2 are vorasidenib, ivosidenib, olutasidenib, and enasidenib. | 100% | 41662580 |
| drug target | Vorasidenib (AG-881) is a dual inhibitor which acts on both IDH1 and IDH2 mutations. | 100% | 40965018 |
| drug efficacy | Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML (clinical trial result). | 100% | 41662580 |
| drug target | Vorasidenib is an inhibitor of mutant IDH1/2 enzymes. | 100% | 41201564 |
| drug efficacy | Vorasidenib is approved for patients with mutant IDH low-grade glioma. | 100% | 41201564 |
| drug efficacy | Vorasidenib is approved for patients with mutant IDH low-grade glioma. | 90% | 41201564 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib, ivosidenib, olutasidenib, and enasidenib were recently approved by the FDA for relapsed/refractory AML. | 90% | 41662580 |
| drug efficacy | Inhibiting IDH mutations with vorasidenib lowers D-2HG (clinical trial result). | 90% | 41252576 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib, an IDH inhibitor, demonstrates promising activity in IDH-mutant low-grade gliomas (clinical trial result). | 90% | 40315665 |
| drug target | Vorasidenib, ivosidenib, olutasidenib, and enasidenib are inhibitors of mutated IDH1 and IDH2, respectively. | 90% | 41662580 |
| drug efficacy | Inhibitors of mutated IDH1 and IDH2, vorasidenib, ivosidenib, olutasidenib, and enasidenib, respectively, were recently approved by the FDA for relapsed/refractory AML. | 90% | 41662580 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug target | PHGDH drives intrinsic resistance to vorasidenib by converting α-KG to D-2HG and maintaining D-2HG concentration despite IDHm inhibition (observed in patient-derived models and patient tissue) | 90% | 40950009 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Inhibiting IDH mutations with vorasidenib is beneficial to patients (clinical trial result). | 90% | 41252576 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Inhibiting IDH mutations with vorasidenib lowers D-2HG (clinical trial result). | 90% | 41252576 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib suppresses D-2HG production and extends progression-free survival in some IDHm glioma patients (clinical trial result) | 90% | 40950009 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Inhibiting IDH mutations with vorasidenib is beneficial to patients (clinical trial result). | 90% | 41252576 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | The phase III INDIGO trial has demonstrated superiority of vorasidenib, a brain-penetrant pan-mutant IDH inhibitor, over placebo in people with non-enhancing grade 2 IDH-mutant gliomas following surgery (clinical trial result). | 90% | 38760442 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Vorasidenib has received FDA approval for IDH-mutant gliomas (clinical trial result). | 90% | 40675687 |
| drug efficacy | Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to reduce D-2-HG levels (demonstrated in preclinical models). | 80% | 38760442 |
| drug efficacy | Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to reduce D-2-HG levels (demonstrated in preclinical models). | 80% | 38760442 |
| biomarker | Deuterium metabolic imaging of D-2HG production from diethyl-[3,3'- 2 H]-α-ketoglutarate provides an early readout of response and resistance to vorasidenib (observed in patient-derived models and patient tissue) | 80% | 40950009 |
| drug efficacy | Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to induce cellular differentiation (demonstrated in preclinical models). | 80% | 38760442 |
| drug efficacy | Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to reduce D-2-HG levels (demonstrated in preclinical models). | 80% | 38760442 |
| drug efficacy | Selective inhibitors of mutant IDH, such as ivosidenib and vorasidenib, have been shown to induce cellular differentiation (demonstrated in preclinical models). | 80% | 38760442 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.